SCHEMBL3184131

SCHEMBL3184131

CC1(COc2ccc3c(c2)N(O)CN3c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.68
RET P07949 3/20 0.68
GAK O14976 1/20 0.68
RIPK2 O43353 1/20 0.68
ULK1 O75385 1/20 0.68
STK10 O94804 1/20 0.68
PRKD3 O94806 1/20 0.68
MAP4K4 O95819 1/20 0.68
LATS1 O95835 1/20 0.68
PAK4 O96013 1/20 0.68
NTRK1 P04629 1/20 0.68
LCK P06239 1/20 0.68
CDK1 P06493 1/20 0.68
APRT P07741 1/20 0.68
PDGFRB P09619 1/20 0.68
PHKG2 P15735 1/20 0.68
NQO2 P16083 1/20 0.68
PDGFRA P16234 1/20 0.68
FECH P22830 1/20 0.68
CDK2 P24941 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14547695 0.84 FLT3 (0.68) FLT3RETGAKRIPK2ULK1
SCHEMBL3182258 0.82 FLT3 (0.76) FLT3RETGAKRIPK2ULK1
Crenolanib SCHEMBL2730601 0.81 FLT3 (1.00) FLT3RETGAKRIPK2ULK1
Crenolanib SCHEMBL29352568 0.81 FLT3 (1.00) FLT3RETGAKRIPK2ULK1
Crenolanib SCHEMBL29350134 0.81 FLT3 (1.00) FLT3RETGAKRIPK2ULK1
Crenolanib SCHEMBL30002138 0.81 FLT3 (1.00) FLT3RETGAKRIPK2ULK1
SCHEMBL3190135 0.80 FLT3 (0.78) FLT3RETGAKRIPK2ULK1
SCHEMBL3184124 0.79 FLT3 (0.73) FLT3RETGAKRIPK2ULK1
SCHEMBL5182882 0.78 FLT3 (0.68) FLT3RETGAKRIPK2ULK1
Crenolanib SCHEMBL29361948 0.76 FLT3 (0.85) FLT3RETGAKRIPK2ULK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016353-A1 BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS HENNE KIRK RUSSELL 2010-01-21 US claimed
EP-1799670-A1 BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS Pfizer Products Inc. (US) 2007-06-27 EP claimed
WO-2006038111-A1 BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS PFIZER PRODUCTS INC. (US) 2006-04-13 WO claimed
US-20100016353-A1 BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS HENNE KIRK RUSSELL 2010-01-21 US disclosed
EP-1799670-A1 BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS Pfizer Products Inc. (US) 2007-06-27 EP disclosed
WO-2006038111-A1 BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS PFIZER PRODUCTS INC. (US) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016353-A1 BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS CCNI, MKI67, CCNT1 FLT3 421/4885RET 1805/4885GAK 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.